Navigation Links
Enzyme allows B cells to resist death, leading to leukemia

B cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in adults and is characterized by the progressive accumulation of mature B lymphocytes in the blood, bone marrow, and lymphatic tissues. It is believed that in the early stages of disease, B-CLL is the result of an undefined defect in the programmed signals that trigger normal B cell death (apoptosis). Livio Trentin and colleagues from Padua University School of Medicine now demonstrate that high levels of expression and altered cellular location of an enzyme in B cells known as Lyn, contributes to the development of B-CLL.

The authors examined leukemia cells from 40 patients with B-CLL and compared them with lymphocytes from normal donors. They found that Lyn was markedly overexpressed in CLL cells and an unusual amount of the enzyme was found in the cell cytosol. In addition, the enzyme was constantly active compared with levels of activity in normal donor cells. The authors went on to show that inhibition of Lyn was able to restore the process of cell apoptosis to normal and treatment of malignant cells with drugs that induce cell death decreased both Lyn expression levels and activity ?suggesting a direct correlation between high Lyn activity and the ability of these B cells to resist apoptosis. The authors suggest that Lyn is involved in the development of B-CLL and that this enzyme therefore represents an attractive target for therapy. The study will appear online on January 13 in advance of publication in the February 1 print edition of the Journal of Clinical Investigation.
'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
2. Novel Enzyme Shows Potential As An Anti-HIV Target
3. Enzyme shown to help protect genomic stability
4. Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol
5. Enzymes newly discovered role may make it target for arthritis treatment
6. Promiscuous Catalytic Activity Possessed by Novel Enzyme Structure
7. Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Enzyme affects hypertension by controlling salt levels in body
10. Enzyme inhibitors block replication of SARS virus
11. Enzyme crystal structure reveals unexpected genome repair functions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2020)... , ... March 13, 2020 , ... ... with Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics ... and medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and ...
(Date:3/9/2020)... ... March 09, 2020 , ... ... rate of 64% last year, as enterprises sought to achieve competitive advantage ... Unfortunately, only 13% of all transformation efforts delivered the intended consequences. , ...
(Date:3/5/2020)... N.J. (PRWEB) , ... March 05, 2020 , ... ... sample preparation and epigenetics research, and MGI Tech (MGI), a subsidiary of global ... library preparation product line in the United States, Europe and Asia Pacific. ...
Breaking Biology News(10 mins):
(Date:3/27/2020)... ... March 25, 2020 , ... ... located centrally in the midwest for high-quality, quick-turn, board-certified reporting. In an ... motivated, independent, professional team that is focused on incredible quality, turnaround time ...
(Date:3/12/2020)... , ... March 12, 2020 , ... ... atomic force microscopy (AFM) technology, increases the business investment in Europe by inaugurating ... , The Grand Opening Ceremony of the new Nanoscience Center Europe took place ...
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will make ... The company will showcase both expanded and emerging offerings that align with the HIMSS ... is designed to be comprehensive, timely, and engaging. From Interoperability and HIE ...
(Date:2/26/2020)... ... 2020 , ... Continuing its leading research on human milk ... safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) HMO. , 3-FL is ... are indigestible and therefore function as a prebiotic by promoting early microbial colonization ...
Breaking Biology Technology: